FORM PTO	PATE	NTS AND OTHER I	TEMS FOR AF	PPLICANT'S	ATTY. DOG 1					
OIPE !					APPLICANT: METABASIS	THERA	PEU	TICS.	INC.	
JUN 1 70	w Sign	MATION DISCLOS	f necessary)	#2	FILING DATE: March 5, 1999			OUP:		
(2)	5									
TRACE		·							_	_
			U.S. P	ATENT DOCU	IMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		IAME	CLASS		SUB CLASS		LING ATE
ja	Ad	3,018,302	01.23.62	Bielefeld, et	t al.					
	AB	5,157,027	10/20 92	Biller, et al.						
· V	AC	5,658,889	8/19/97	Gruber, et a	ıl.			•		
1									.L	
•			POREIGN	PATENT DO	CUMENTS		<u>.</u>			
EXAMINER						<u> </u>	Т.	SUB	TRANS	LATION
INITIAL		DOCUMENT NUMBER	DATE	COL	JNTRY	CLASS		ASS	YES	NO
4.	AD	0 002 062 A	30.05.78	EP (Abstract)		<u> </u>			
	AE	0 072 531 A	23,62.83	EP (Abstract)					
	AF	0 158 057 A	16.10.85	EP (Abstract						•
	AG	0 180 276	28.12.88	EP						
	AH	0 261 283	22.09.86	EP						
	Al	0∕161 955 A	21.11.85	EPO						
	AJ	0 338 372 A	25.10.89	EPO		X				
	AK	0 353 692 A	07.02.90	EPO						
X	AL	0 481 214 A	22.04.92	EPO						
A	AM	492 738 A	30.06.70	СН				1		
<u>V</u>	AN	16 93 219 _t A	17.09.70	DE (Abstract)	0					
		@11	die	11/1			+			
EXAMINER:	I	m		DATE	CONSIDÈRED:	19/0	<u>'</u>			
EXAMINE ine through	CHAUC	tial if reference is con if not in conform	onsidered, wh	nether or not cite considered. In	ation is in confo	mance whis form	vith N with	MPEP (609; Di	aw

		····	<u> </u>	<u> </u>							
4		TO-144	·			ATTY. DOG 37 R 30727.0013.CI			ial n 518,5		
		INFOR	ints and other it Rmation disclosi			applicant: METABASIS T	HERA	•			
	9,	16) saveral sheets i	i necessary)		FILING DATE: March 5, 1999		GR0 161)UP:		
-	im.	1100	S C F F F F F F F F F F F F F F F F F F								
	A .	20	1	FOREIGN	PATENT DO	ocuments -	-				
IP	MINE	B RADE	DOCUMENT NUMBER	DATE		DUNTRY	CLASS		BUB ASS PS	Y23	LATION NO
	K	1 AO	35 12 781 A1	10.04.85	DE (and En U.S. Patent	glish language No. 4,952,740)					
		AP	96/01267 A	18.01.96	wo						
L		AQ	97/03679 A	06.02.97	wo						
<u> </u>		AR	98XQ9668 A	12.03.98	wo	/.					
<u> </u>		AS	98/39342	11.09.98	wo						-
		AT	98/39343	11.09.98	wo /			\prod			
L		AU	98/39344	1.09.98	wo						
								7			
		OTH	er documents	(Ipcludin	g Author, Ti	de, Date, Pertir	rent F) බලුළු		。)	
q	W	AV	"Patent Abstract (Yamishata Koji;	s of Japan," Nippon So	Vol. 4998, N da Co. Md), 1	o. 1, 30 January 6 September 199	1998 8 17	JP ()9 2 4	1284 A	
		AW	DeLograbaert, et	al., "N-Phos on of Neutra	phonomethyl I Endoprotida	Dipeptides and T	heir P	hosp Inhil	honat bitors	le Prod J. Me	rugs, <u>d</u> .
.}		AX	Edmunson, et al	., "Cyclic Or he 4-Phený 2-Benzylami	ganophospho l-1,3,2λ5-dio no-4-phenyl-	orus Compounds. caphospherinane i,3,2-dioxapiosp	Series	X-R	av M	olecula	r I
		AY	Farquhar, et al., fluorouridine: a n (FDUMP)'" J. Me	"5'-'4-(Pivalo nembrane-p	oyloxy)-1, 3, 2	odrug of 5-fluoro-	n an -2 2'-020	2-y][-:	2'-ded dylic a	oxy-5- acid	
d		AZ	Farquhar, et al., '72(3): 3⁄24 (1983	'Biologically			tive Gı	oups	." <u>J.</u> F	harm.	Sci.
		Ç	ell a	9/1	cal	25		,			-
MAX3 max3	INER	DR	aux Ol	U.D.	DATE	CONSIDERED:	9/0	アレ			
EXA line t	MIN	ER: Ini sh citati	tial if reference is co on if not in conform	onsidered, whance and not	ether or not ci considered. In	tation is in conform	nance v is form	vith N with	IPEP (609; Dr	aw

										
FORM	PTO-14	99	ATTY. DOC	Serial No. 09/518,501						
LIS NP E	DSIMIR .	'ents and other items for applicant's Drmation disclosure statement	APPLICANT: METABASIS THERA							
*		(Use several sheets if necessary)	FILING DATE: March 5, 1999	Group: 1614						
100 1 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1										
N.		HER DOCUMENTS (Including Author, Ti	ide, Date, Perdinent (Pages, etc.)						
STE TE	N BA	Farquhar, et al., "Synthesis and Biologica oxazaphosphorinan-2-yl)-ß-D-arabinosyl dioxazaphosphorinan-2-yl)-ß-D-arabinos [ß-D-Arabinofuranosyl]adenine 5'-Monop (1985)]adenine and 9-[5'-(2-O yl]adenine: Potential Ne	xo-1,3,2- extral Precursors of 9-						
	Farquhar, et al., "Synthesis and Biological Evaluation of Neutral Derivatives of 5-BB Huoro-2'-deoxyuridine 5'-Phosphate," J. Med. Chem. 26: 1153-1158 (1983)									
	ВС	Freed, et al., "Evidence For Acyloxymethyl Esters of Pyrimidine 5'- Deoxyribonucleotides as Extracellular Sources of Active 5'-Deoxyribonucleotides in Cultured Cells," Biochem. Pharmac. 38, 3193-3198 (1989)								
	8D	Hillers, et al., Analogs of pyrimidinemone (1,4-dihydroxy-2-gentyl)thymine and 1-(1	lillers, et al., "Analogs of pyrimidinemono-and polynucleotides. IV. Phosphates of 1-1,4-dihydroxy-2-pentyl)thymine and 1-(1,3-dihydroxy-2-propyl) uracil." Khim Geterotski oedin 5:678-683 (1978). Cham Abst. v 89 no 17; abst no 146864a							
	BE	Hunston, et al., "Synthesis and Biological Derived from 2'-Deoxy-5-ilyorouridine," J	Properties of Some Cv	clic Phosphotriesters						
	BF	Kryuchkov, et al. Izv. Akad. Nauk SSSR.	Ser. Khim. 6: 1201-12	48 (1987)						
	8G	Lok, et al., "Neurotoxicity associated with treatment of chronic hepatitis B virus infe (1984)	adenine arabinoside m	onophosphate in the						
	ВН	Ludeman, et al., "Synthesis and Antitumo Preparation, Kinetic Studies, and Antican and Similar Compounds Related to the C Aldophosphamide," J. Med Chem. 29, 71	cer Screening of "Phen vclophasphamide Meta	vi ketophos phamide"						
·	ВІ	Meier, et al., "Cyclic Saligenyl Phosphotre didehydrothymidine (d4T) – A New Pro-N Lett. 7: 99-104 (1977)	eisters of 2', 3'-Dideoxy- ucleotide Approach," <u>B</u>	-2', 3'- ioorg. Med. Chem.						
	BJ	Meyer, et al., "2"-O'-Acyl-6-thioinosine Cy Thiolnosinic Acid," J. Med. Chem. 22: 811	clic 3', 5'-Phosphates @ I-815 (1979)	s Prodrugs of						
	ВК	Neidlein, et al., "Mild Preparation of 1-Ber Application to the Synthesis of Cyclic Pho Amides," Meterocycles 35: 1185-1203 (19	sphonic Deisters and C	honia Dichlorides: Cyclic Monoester						
		ATIL OKRILICO	alos ,							
EXAMIN Examine		Omes III DATE	CONSIDERED:	02						
ling thr	ough cita	nitial if reference is considered, whether or not cition if not in conformance and not considered. It to applicant	itation is in conformance on clude a copy of this form	with MPEP 609; Draw with next						

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT OPE (Use several sheets if necessary) ATTY, DOC 10 NO. 30727.0013.CIP1 09/518,501 APPLICANT: METABASIS THERAPEUTICS, INC. FILING DATE: March 5, 1999 1614

- WW.	5/	
Serve .	STH	ER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
1	BL	Nifant'ev, et al., "1,3,2, - Diazaphodsphorinanes", <u>Zh. Obshch. Khim.</u> , Vol. 49, No. 1, 1979, Pages 64-74 (and English version as translated in corresponding English language publication)
	BM	Nifantyev, et al., "Synthesis and Structure of Some Stable Phospholane- Phospholanes," Phos. Sulfur & Silicon 113, 1-13 (1996)
	BN	Predvoditelev D., et al., "Glycero-2-hydroxymethylene phosphates" <u>Journal of Organic</u> Chemistry of the USSR (English Translation 13:1489-1492 (1977))
•	ВО	Predvoditelev, D. et al., "Synthesis of lipids and their models on the basis of glycerol alkylene phosphites. V. Cyclic phosphatidylglycerol and phosphatidylhydroxyhomocholine" Journal of Organic Chemistry of the USSR (English Translation 17:1156-1165 (1981)
	BP	Shaw & Cundy, "Biological Screens of PMEA Prodrugs," Pharm. Res. 10 (Suppl) S24 (1993)
	BQ	Shih, et al., "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2-dioxaphosphorinane-2-oxides," Bull. Inst. Chem. Acad. Str., 41: 9-16 (1994)
	BR	Starrett, et al., "Synthesis, Oral Bioavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)-ethyl]adenine (PMEA)," <u>J. Med. Chem.</u> 37: 1957-1864 (1994)
	, BS	Yamanaka, et al., "Metabolic Studies on BMS-200475, a New Antiviral Comound Active against Hepatitis B Virus," Antimicrob. Agents Chemoth. 43, 190-193 (1999)
4	ВТ	Zon, ét al., "4 Cyclophosphamide Analogues," Prog. Med. Chem. 19: 205-246 (1982)
•	J	Il dox receté

EXAMINER:	$\int_{-\infty}^{\infty} O(100)$	DATE CONSIDERED:
Examiner	War Will	7/9/02
EXAMINER	: Initial if reference is considered, whether or	not citation is in conformance with MPEP 609; Draw
line through	citation if not in conformance and not conside	red. Include a copy of this form with next

Please type a plus sign (+) inside this bo Under the Papercroft Reduction Act of 19(3) Substitute for form 1449A/PTO

Sheet

FEB 2 5 2002 55 Son or polytran ena snoon

PTO/SB/08A (08-00)

Approved for Jugh 10/31/2022 OMB 0851-0031
Server and Tradement Office: DEPARTMENT OF COMMERCE
and to a collection of information unloss contains a veild OMB central number

& TRAINE WARM Information disclosure STATEMENT BY APPLICANT

(use es many sheets as necessary) of

Complete If Known Application Number 09/318,501

March 3, 2000 Filing Date First Named Inventor Erlon 1624 Group Art Unit

T. McKenzie Examiner Name

030727.0013.CIP1 Attorney Docket Number

	U.S. PATENT DOCUMENTS									
Examinar Initialo*	Cito No.'	U.S. Pate Number	nt Document ions Costs ³ (# targesn)	Nome of Patentee or Applicant of Cited Document	Dato of Publication of Cited Document MM-DD-YYYY	Pegga, Columbo, Urco, Whod Roberni Pewedges of Richard Flyung Appaur				
					<u></u>					

	FOREIGN PATENT DOCUMENTS									
Enominer Cite	Cite	Foreign Patent Document			Name of Potentes or Applicant of Cited	Date of Publication of . Cited Document	Pager, Columnia, Lines, Weste Reference			
initials			Number*	(control	Document	MM-DD-YYYY	Principa or Relevant Figures Appers	79		
		i								
						<u> </u>		—		
						<u> </u>				
				<u></u>		<u></u>	<u> </u>	=		

	===		non patent literature documents	
Examir Initials		Cite No.1	includo rema of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the liam (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-lasue mumbor(s), publisher, city end/or country where published.	72
1	V	AA	Coppi, et al., "Lewis Acid Mediated Condensation of Alkenols and Aldehydes. A Selective Synthesis of Tetrahydropyrans and Oxepanes," J. Org. Chem., Vol. 53, No. 4, 911-913 (1988)	
		AB	Lohr et al., "Targeted chemotherapy by intratumor injection of encapsulated cells engineered to produce CYP2B1, and ifosfamide activating cytochrome P450," Gene Therapy, 5, 1070-1078 (1988).	
	-	AC	Bijsterbosch, et al., "Disposition of the Acyclic Nucleoside Phsophonate (S)-9-(3- Hydroxy-2-Phosphonylmethoxypropyl)Adenine," Antimicrobial Agents and Chemotherapy, "Vol. 42, p. 1146-1150 (May 1998).	
V		AD	de Waziers, et al., "Cytochrome P 450 Isoenzymes, Epoxide Hydrolase and Glutathione Transferases in Rat and Human Hepatic and Extrahepatic Tissues1," The Journal of Pharmacology and Experimental Therapeutics, Vol. 253, No.1, p. 387-394 (1989).	

			<u> </u>	<u> </u>
Examiner Ous McUs	Date Considered	2/	12/	<i>9</i> 3

^{*} Unique distinct designation number. * Soo estached Kinds of U.S. Petent Documents. * Enter Office that Issued the document, by the two-latter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the raign of the Emparer must precede the carla number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language Translation in attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be cent to the Chief Information Officer, U.S. Patent and Trademark Office. Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patenta, Washington, OC 20231.

^{*}EXAMINER: Initial if reference considered, whather or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this remarks next communication to applicant.

Please type a plus sign (+) inside this box 3

Sheet

FEB 2 5 2002 2

PTC/SB/08A (08-00)
Approved for Let dyough 10/31/2002 OMB 0851-0031

S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE fond to a collection of information unless it contains a valid CMB control number

Under the Paperwork Reduction Act of 1995, no pensors

Substitute for form 1449A/PTO

TRADENS

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 09/518,501

Filing Date March 5, 1999

First Named Inventor Erion

Group Art Unit 1824

(use as many sheets as necessary)

Examiner Name T. McKenzie
Attorney Docket Number 030727,0013,CIP1

		1 /	
Examiner Signature Quint UI	Date Considered	2/13/0	5
	Considered	(C) (C)	<u> </u>

*EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through cliation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Jepanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Tradement Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<u>'</u>									
FORM PTC-1					ATTY. DOCKSINO. SERIAL NO. 30727.001 1111 09/518,501				
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT					APPLICANT: METABASIS	S THERAF	PEUTICS,	NC.	
₩U	(Us	e several sheets if	necessary)		FILING DATE March 5, 19	E: GROUP:			
	/	0186/			_,¿C				
	7	FEB 2 5 2007 55					MAR	VAN	
	PART		U.S. PA	TENT DOC	UMENTS	"ECH	CEAN	2002	
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SAS 60	FILING DATE	
1cm	AA	3,018,302	01/23/62	Bielefeld,	et al.	260	46	300	
Juy.	AB	5,157,027	10/20/92	Biller, et al		514	167	<u> </u>	
JUM.	AC	5,658,889	8/19/97	Gruber, et	al.	1514	143		

·	FOREIGN PATENT DOCUMENTS										
EXAMINER							SUB		TRANS		
INITIAL	ļ	DOCUMENT NUMBER	DATE	COUNTRY	CLA	<u>ss_</u>	CLASS		YES	NO	
IM	AD	0 002 062 A1	30.05.79	EP (and English language - Abstract)							
TU	AE	0 072 531 A1	23.02.83	EP (and English language Abstract)							
C	AF	0 158 057 A	16.10.85	EP (U.K. English language translation)							
	AG	0 180 276 A1	28.12.88	EP							
	АН	0 261 283 A1	22.09.86	EP							
	AI	0 161 955 A1	21.11.85	EPO							
	AJ	0 338 372 A2	25.10.89	EPO							
	AK	0 353 692 A2	07.02.90	EPO				,			
	AL	0 481 214 B1	22.04.92	EPO							
	АМ	492 738	30.06.70	CH (and English language Abstract)							
	AN	987,378	17.09.70	UK							

EXAMINER:	Vi	DATE CONSIDERED:	18	03.
EXAMINER: Initial if reference is ine through citation if not in confor communication to applicant	considered, whether or	r not citation is in confo cred. Include a copy of	rma this	nce with MPEP 609; Draw form with next

FORM PTO-1449

list of patents and other items for applicant's information disclosure statement

ATTY. DOCY NO. 30727.00 LIP1

Serial No. 09/518,501

APPLICANT:

METABASIS THERAPEUTICS, INC.

	(Use several sherein decerally)					Filing Date: Group: March 5, 1999 1614			
				i i i i i i i i i i i i i i i i i i i	PATENT DO	CUMENTS		MA	COVE
examii Initi			DOCUMENT NUMBER	MARK CENT	ω	UNTRY	CLASS	FC COURSE	YES COORO
	M	AO	35 12 781 A1	10.04.85	DE (and Eng U.S. Patent	glish language No. 4,952,740)		100	YES 70/20 F9 1600/2900
		AP	96/01267	18.01.96	wo				
		AQ	97/03679	06.02.97	wo			<u> </u>	
		AR	98/09668	12.03.98	wo				
		AS	98/39342	11.09.98	wo				
	7	AT	98/39343	11.09.98	wo				
	\square	AU	98/39344	11.09.98	wo				

	OTHER DOCUMENTS (Including Author, Title, Date, Perdinent Pages, etc.)							
	1v	AV	"Patent Abstracts of Japan," Vol. 1998, No. 1, 30 January 1998 & JP 09241284 A (Yamishata Koji, et al.; Nippon Soda Co. Ltd), 16 September 1997					
DeLombaert, et al., "N-Phosphonomethyl Dipeptides and Their Phosphonate a New Generation of Neutral Endopretidase (NEP, EC 3.4.24.11) Inhibitors, J. AW Chem. 37: 498-511 (1994)								
		AX	Edmunson, et al., "Cyclic Organophosphorus Compounds. Part 23. Configurational Assignments in the 4-Phenyl-1,3,2λ5-dloxaphosphorinane Series. X-Ray Molecular Structure of <i>cis</i> -2-Benzylamino-4-phenyl-1,3,2-dloxaphosphorinane 2-Oxide," <u>J. Chem. Res. Synop.</u> , 5: 122-123 (1989)					
		AY	Farquhar, et al., "5'-'4-(Pivaloyloxy)-1, 3, 2-dioxaphosphorin an -2-y]!-2'-deoxy-5- fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FDUMP)" J. Med. Chem. 38:488-495 (1995)					
		AZ	Farquhar, et al., "Biologically Reversible Phosphate-Protective Groups," <u>J. Pharm. Sci.</u> 72(3): 324-325 (1983)					

EXAMINER: Examine	Marches CAM C	19	DATE CONSIDERED:	glor
line through ci	itation if not in conformance	•		rmance with MPEP 609; Draw this form with next
communicatio	n to applicant			•

	•			
F (O I PE	atty. Dock-t no. 30727.001 IP1	sertal m 09/518,5	
	List of patents and other items for applicant's \ information disclosure statement \$ 200.	applicant: Metabasis Thera	PEUTICS	Pro Co
	(Use several sheets if necessary)	Filing Date: March 5, 1999	Group: 164%	Mas
_	S Mahama		12575	7

	- TAIL HAVE	180 CSa_	102
. 0	THER DOCUMENTS (Including Author, Tide, Date, Pe	ertinent Pages, etc.	TED.
M BA	Farquhar, et al., "Synthesis and Biological Evaluation on oxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine and dioxazaphosphorinan-2-yl)-ß-D-arabinosyl]adenine: Post [ß-D-Arabinofuranosyl]adenine 5'-Monophosphate," J. (1985)	otential Neutral Precurs	sors of 9-
88	Farguhar, et al., "Synthesis and Biological Evaluation of Fluoro-2'-deoxyuridine 5'-Phosphate," J. Med. Chem.		if 5-
BC	Freed, et al., "Evidence For Acyloxymethyl Esters of P Deoxyribonucleotides as Extracellular Sources of Activ Cultured Cells," <u>Biochem. Pharmac.</u> 38: 3193-3198 (19	/e 5'-Deoxyribonucleoti	ides in
80	Hillers, et al., "Analogs of pyrimidinemono-and polynuc (1,4-dihydroxy-2-pentyl)thymine and 1-(1,3-dihydroxy-2-) Soedin 5:678-683 (1978). Chem Abst. v 89 no 17; abs	2-propyl) uracil." <u>Khim (</u>	
BE	Hunston, et al., "Synthesis and Biological Properties of Derived from 2'-Deoxy-5-fluorouridine," J. Med. Chem.)triesters
BF	Kryuchkov, et al., <u>Izv. Akad. Nauk SSSR, Ser. Khim.</u> 6	: 1201-1248 (1987)	
80	Lok, et al., "Neurotoxicity associated with adenine arat treatment of chronic hepatitis B virus infection," <u>J. Antio</u> (1984)		
. BH	Ludeman, et al., "Synthesis and Antitumor Activity of C Preparation, Kinetic Studies, and Anticancer Screening and Similar Compounds Related to the Cyclophosphar Aldophosphamide," J. Med Chem. 29, 716-727 (1986)	g of "Phenyl ketophos p	
81	Meier, et al., "Cyclic Saligenyl Phosphotreisters of 2', 3 didehydrothymidine (d4T) – A New Pro-Nucleotide App Lett. 7: 99-104 (1997)		Chem.
ВЈ	Meyer, et al., "2"-O'-Acyl-6-thioinosine Cyclic 3', 5'-Pho Thiolnosinic Acid," J. Med. Chem. 22: 811-815 (1979)	esphates as Prodrugs o	of
₩ BK	Neidlein, et al., "Mild Preparation of 1-Benzyloxyiminoa Application to the Synthesis of Cyclic Phosphonic Deis Amides," <u>Heterocycles</u> 35: 1185-1203 (1993)		

	· · · · · · · · · · · · · · · · · · ·						
EXAMINER:		DATE CONSIDERED:					
Examiner	Minus Ille II.	719100					
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next							
communication							

Information Disclosure Statement - Section 9 PTO-1449

FORM PTO-1449

ATTY. DOCKET NO. 30727.001

SERIAL NO. 09/518,501

APPLICANT:

METABASIS THERAPEUTIO

FILING DATE:

GROUP

(Use several sheets if necessary)

LIST OF PATENTS AND OTHER ITEMS FOR APPLICATION DISCLOSURE STATEMENT

INFORMATION DISCLOSURE STATEMEND

FEB 2 5 2007

March 5, 1999

1614

		IER DOCUMENTS (Including Kothor, Title, Date, Pertinent Pages (20)
	OTH	
JW BL		Nifant'ev, et al., "1,3,2, - Diazaphodsphorinanes", Zh. Obshch. Khim., Vol. 49, No. 2900 1979, Pages 53-61.
	ВМ	Nifantyev, et al.,"Synthesis and Structure of Some Stable Phospholane- Phospholanes," Phos. Sulfur & Silicon 113, 1-13 (1996)
	BN	Predvoditelev D., et al., "Glycero-2-hydroxymethylene phosphates" <u>Journal of Organic</u> Chemistry of the USSR (English Translation 13:1489-1492 (1977))
	ВО	Predvoditelev, D. et al., "Synthesis of lipids and their models on the basis of glycerol alkylene phosphites. V. Cyclic phosphatidylglycerol and phosphatidylhydroxyhomocholine" <u>Journal of Organic Chemistry of the USSR (English Translation</u> 17:1156-1165 (1981)
	ВР	Shaw & Cundy, "Biological Screens of PMEA Prodrugs," Pharm. Res. 10 (Suppl) S-294 (1993)
	BQ	Shih, et al., "Preparation and Structures of 2-Dimethylamino-4-phenyl-1,3,2-dioxaphosphorinane-2-oxides," Bull. Inst. Chem. Acad. Sin, 41: 9-16 (1994)
	BR	Starrett, et al., "Synthesis, Oral Bioavailability Determination, and <i>in Vitro</i> Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)-ethyl]adenine (PMEA)," <u>J. Med. Chem.</u> 37: 1857-1864 (1994)
	BS	Yamanaka, et al., "Metabolic Studies on BMS-200475, a New Antiviral Comound Active against Hepatitis B Virus," Antimicrob. Agents Chemoth. 43, 190-193 (1999)
W	вт	Zon, et al., "4 Cyclophosphamide Analogues," Prog. Med. Chem. 19: 205-246 (1982)

EXAMINER:	n 21	0/11	77,	7. •	DATE CONSIDERED:	r./	
Examiner	MMAG		X_{k}	1	779	1_	00
EXAMINER!	Initial if refere	nce is consider	ed.	whether or	not citation is in conforma	nce v	vith MPEP 609; Draw

line through citation if not in conformance and not considered. Include a copy of this form with next

💠 🤄 racid ciril ebian (+) ngle cuitq o eqr

Sheet

PTO/SBIGGA (08-00)
Approved for use through 18/31/2002. CMB 0381-0031
U.S. Potent and Yrodoment Office: U.S. DEPARTMENT OF COMMERCE maior ero Posservant Roducilen Act of 1993, no parceno one required to necessat to a collection of information exclass in contesting o volta OACS contest municipal

Subsettute for form 1448APTO

INFORMATION DISCLOSURE Statement by applicant

(use as many sheets as necessary)

Of

Complete If Known						
Application Number	09/518,501					
Filing Data	March 3, 2000	Q:				
First Named Inventor	Erion of al.	. \$				
Group Art Unit	1624	70				
Examiner Name	McKanzla, T.	SAY.				
Altomay Decitet Number	45128.00013.RCE (CIP1)	THE SE				
	~					

			U.S. PATENT DOCU	ments	
Expansion Inhibitor	Cito No.'	V.S. Patent Decument Rumber Wind Code Witness		Octo of Publication of Chod Consument MM-QD-YYYY	Pogos, Ceberron, Urion, Wilmon Relevant Pomocpus er Account Populars Appear
900		6,054,587	Reddy et al.	04/25/00	
(·		6,110,903	Kasibhatla et al.	08/29/00	
		6,284,748	Dang et al.	09/04/01	
		6,294,672	Reddy et al.	09/25/01	
		6,312,662	Erion et al.	11/06/01	
		6,399,782	Kasibhatla et al.	06/04/02	
		6,489,476	Dang et al.	12/03/02	
					· · · · · · · · · · · · · · · · · · ·
					

	Foreign patent documents									
Eneminer Initials	Cite No.1	Office)	Foreign Potent Doc Number	muteril Fra Costs, fil.	Name of Potentie or Applicant of Cited Document	Octor of Publication of Cited Octoring MM-DD-YYYY	Payer, Columbia, Llum, When Refrence Postages or Refrence Plymon Appear	rs		
	•,									
 	-							\vdash		
لييا		لسييا				<u> </u>		ليا		

Non patent literature documents							
Exciminar Initicis	Citio No."	Daduste name of the curber (in CAPITAL LETTERS), title of the curber (schon representate), title of the from (beset, megazina, journes, country countr					
			L				
			•				

	<u> </u>					
Examines Signsture	Jon	Mello	Date . Considered	4/16	104	
	9					

"EXAMINER: Initial III reterance considered, whother or not pitation is in contempose with MPEP 608. Show the through citation is not in contempose and misconsidered, traduce copy of this form with next assumptication to applicant.

*Unique eliation designation number. * See disented kines of U.S. Petent Decuments. * Enter Calco that based the decument, by the two-lotter code (WIPO Sembard ST.3). * For Japanese potent decuments, the Indicates of the year of the Caparest must preced the code number of the potent decument. * Kind of decument by the appropriate symbols as Indicated on the decument water WIPO Standard ST, 16 & possible. * Applicant to to place or check man, have it English language Translation to effect on the decument water WIPO Standard ST, 16 & possible.

Burdan Hour Statement. This form is continued to take 2.0 hours to complete. Time will vary depending upon the recode of the individual case. Any comments on the amount of time you are required to complete this form should be cent to the Crief Information Officer, U.S. Patent and Tradement Office, Washington, OC 2021. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Academic Commissioner for Patento,

Please type a plus aign (+) inside this box > +

STENT

Sheet

Substitute for form 1449A/PTO

PTO/SB/08A (08-00)

e type a plus sign (+) inside this box -> + Approved for use through 10/31/2002. OMB 0351-0031

U.S. Patent and Tredemark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

> (use as many sheets as necessary) of

Complete it Kn. wn						
Application Number	09/518,501	_				
Filing Date	March 3, 2000	_				
First Named Inventor	Erion et al.					
Group Art Unit	1624	_				
Examiner Name	T. McKenzie	_				
Attorney Docket Number	45198.00013.RCE	_				

				U.S. PATENT DOCU	MENTS	· · · · · · · · · · · · · · · · · · ·
Examiner	Cite	U.S. Patent C	ocument	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Unes,
initiets*	No.	Mucillar .	IGnd Code ⁸	of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
	ļ	ļ				
						
						·
					,	
·	 					
						•
						*
	L	<u> </u>				

					ATENT DOCUMEN	TS		
Examiner Cite	Cite	Ĺ	Foreign Patent Do		Name of Patentee or	Date of Publication of	Pages, Columns, Lines,	T-
Initials	No.1	Office ³	Number*	Kind Code (// Incres)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passagus or Relevant Figures Appear	7
		lacksquare						
							-	T-
L 1		اـــــا						

		NON PATENT LITERATURE DOCUMENTS	
Exeminer Initiats	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	To
8		FARQUHAR et al., "Synthesis and Antitumor Evaluation of Bis[pivaloyloxy]methyl] 2'-Deoxy-5- fluorouridine 5'-Monophosphate (FdUMP): A Strategy to Introduce Nucleotides into Cells," J. Med. Chem., 37:3902-3909 (1994).	
1	\	LEFEBVRE, et al., Mononucleotide Phosphotriester Derivatives with S-Acyl-2-thioethyl Bioreversible Phosphate-Protecting Groups: Intracellular Delivery of 3'-Azido-2',3'-dideoxythymidine 5'-Monophosphate," J. Med. Chem., 38:3941-3950 (1995).	

		/	/	,
Examiner Signature On Maria	Date Considered	4//	6/6	4
*EXAMINER: Initial If reference considered, whether or not citation is in		2 2 2	/ /	

and not considered. Include copy of this form with next communication to applicant.

'Unique citation designation number. ² See attached kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Places type o plus oign (+) inside this box -> +

O

FEB 27

ALEND B. LE

Sheet

PTO/SB/08A (08-00)

032465.00013.RCE (CIP1)

a ype o paus olgn (+) Instite this box -> *

(U.S. Potent and Tredemant Critics: U.S. DEPARTMENT OF COMMERCE

(U.S. Potent and Tredemant Critics: U.S. DEPARTMENT OF COMMERCE

(Under the Paportrent Roduction Act of 1885, no parcens are required to respond to a consistent of termination unition in contains o visit Calle control number Substitute for form 1448A/PTO Complete If Known Application Number nformation disclosure 09/518,501 Filing Date March 3, 2000 statement by applicant First Named Inventor Erion at al. Group Art Unit 1624 (use as many sheets as necessary) Examiner Name T. McKenzie

Attorney Doctat Number

				U.S. PATENT DOCU	Ments	
Examinar Initiato*	Çîte No.'	U.S. Paten Number	Document Para Codo Viencem	Name of Petentes er Applaant of Cited Decumant	Orto of Publication of Clied Document MM-DD-YYYY	Pogna, Colonia, Cina, Wanto Rothions Pognagos er Rothions Figuros Apponi
						7,833,921

				FOREIGN PA	ATENT DOCUMEN	TS		_
Exeminer Initials	Cite No.	Ottico,	Foreign Patent Dos Number ⁶	turnent Kird Cody (y krovo)	Name of Patentes er Applicant of Cited Decement	Date of Publication of Cited Determent MM-DD-YYYY	Proper Colorada Licas Where Rederron Property or Rederron	
							Pyreso Agents	屵

<u> </u>		(NOM PATENT LITERATURE DOCUMENTS .	
Excuminor Initiato	Cite No.'	Include neme of the author (InCAPITAL LETTERS), title of the enticle (chan appropriate), title of the Item (besit, megazine, journest, sorte), symposium, catalog, atc.), date, page(o), volume-lesus number(s), publisher, city and/or country where published.	T*
8		Beaucage and Iyer, "The Synthesis of Modified Oligonucleotides by the Phosphoramidite Approach and Their Applications," Tetrahedron, 49(28):6123-6194 (1993).	
		Borch and Millard, "The Mechanism of Activation of 4-Hydroxycyclophosphamide," <u>J. Med. Chem.</u> , 30:427-431 (1987).	
		Cooper et al., "Use of Carbohydrate Derivatives for Studies of Phosphorus Stereo-chemistry. Part II. Synthesis and Configurational Assignments of 1,-3,2-Oxathiaphosphorinan-2-ones and 1,3,2-Dioxaphosphorinan-2-thiones," J. Chem. Soc., Perk. Trans. 1, (10):1049-1052 (1974).	
		De Clercq et al., "A Novel Selective Broad-spectrum Anti-DNA Virus Agent," Nature, 323:464-467 (1986).	
		Farquhar et al., "Synthesis and Antitumor Evaluation of Bis[(pivaloyloxy)methyl] 2'-Deoxy-5-fluorouridine 5'-Monophosphate (FdUMP): A Strategy to Introduce Nucleotides into Cells," J. Med. Chem., 37:3902-3909 (1994).	

Examinar Signature	Considered Considered	4/16/61
EMMINED IN		

^{*}EXAMINER: Initial it reference considered, whether or not clienth is in conformance with MPEP 800. Drown through charton is not in conformance and not considered. Include copy of this form with next communication to applicant.

^{*} Unique citation designation number. * See attended Kindo of U.S. Potent Decuments. * Enter Office that issued the decument, by the fivo-latter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emparer must precede the codel number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under VVIPO Standard ST. 16 if possible. * Applicant is to gless a check mark hard if English tenguage Transaction is attached.

Burden Neur Statement: This term is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the Individual case. Any comments on the arrount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Tradement Officer, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002, QMB 0851-0931

U.S. Patent and Tredement Calca: U.S. DEPARTMENT OF COMMERCE
Under the Papercent Reduction Act of 1895, no parcent ore required to respond to a collection of information unions it contains a well OMB control number

Substitute for form 1448AFPTO Complete If Known Information disclosure Application Number 09/518,501 Filing Data March 3, 2000 statement by applicant First Named Inventor Erton et al. Group Art Unit 1624 (use as many sheets as necessary) Examiner Name Y. McKenzie of Attorney Doctet Number 032485.00013.RCE (CIP1)

		non patent literature documents	
Exeminor .	Cito	Implies come of the color of CORTAL STATES AND	
Initials	No.	Include name of the author (in CAPITAL LETTERS), title of the critical (ches appropriate), title of the item (beest, magazine, journal, serial, sympocium, estatog, etc.), detc., gegalo), votume-issue numberlo), publisher, etty chefor country cheste published.	T ²
1 1 /	ł	Pris and Bundgaard, "Prodrugs of Phosphates and Phosphonates: Novel Licentific as	
		Regative Charges of these Groups," <u>Euro, J. Pharm. Sci.</u> , 4:49-59 (1996).	
		Harada et al., "Resoluation of 1,3-alkanediols Via Chiral Spiroketals Derived from t- Menthone," <u>Tetrahedron</u> , 28(41):4843-4846 (1987).	
		Khorana et al., "Cyclic Phosphates. III. Some General Observations on the Formation and Properties of Five-, Six- and Seven-membered Cyclic Phophate Esters," <u>JACS</u> , 79:430-436 (1957).	
		Korba et al., "Liver-targeted Antiviral Nucleosides: Enhanced Antiviral Activity of Phosphatidyl-dideoxyguanosine Versus Dideoxyguanosine in Woodchuck Hepatitis Virus Infection In Vivo," Hepatology, 23(5):958-963 (1996).	
	0	Lefebvre et al., "Mononucleoside Phosphotriester Derivatives with S-acyl-2-thioethyl Bioreversible Phosphate-protecting Groups: Intracellular Delivery of 3'azido-2',3'dideoxythymidine 5'-monophosphate," J. Med. Chem., 38:3941-3950 (1995).	
		Ludeman et al., "Synthesis and Antitumor Activity of Cyclophosphamide Analogues. 4. Preparation, Kinetic Studies, and Anticancer Screening of "Phenylketophosphamide" and Similar Compounds Related to the Cyclophosphamide Metabolite Aldophosphamide," <u>J. Med. Chem.</u> , 29:716-727 (1986).	
		McGuigan et al., "Intracellular Delivery of Bioactive AZT Nucleotides by Aryl Phosphate Derivatives of AZT," J. Med. Chem., 36:1048-1052 (1993).	
		Mosbo and Verkade, "Dipole Moment, Nuclear Magnetic Resonance, and Infrared Studies of Phosphorus Configurations and Equilibria in 2-R-2-Oxo-1,3,2-dioxaphosphorinanes," J. Org. Chem., 42(9):1549-1555 (1977).	
		Nakayama and Thompson, "A Highly Enantioselective Synthesis of Phosphate Triesters," L. Am. Chem. Soc., 112:6936-3942 (1990).	
		Ramachandran et al., "Efficient General Synthesis of 1,2- and 1,3-diols in High Enantiomeric Excess via the Intramolecular Asymmetric Reduction of the Corresponding Ketoalkyl Diisopinocampheylborinate Intermediates," Tetrahedron, 38(3):761-764 (1997).	
			- 11

		·//	
Examiner	Date	1/1/1/	Dell
Signature	Consider Consider	red ///8/0	

"EDAMINER: Initial II reteronce considered, whether or not provide is in conformance with MPEP 609. On the litrough citation is not in conformance and not considered. Include copy of this form with nost communication to applicant.

Burden Mour Statement: This form to estimated to take 2.0 hours to complete. Time will vary depending upon the neede of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Intermettion Officer, U.S. Patent and Tradement: Officer, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Potents, Washington, DC 20231.

^{&#}x27;Unique disting designation number. 2 See electhed Kinds of U.S. Potent Documents. 2 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 9 For Japanese patent documents, the indication of the reign of the Emperor must precede the early number of the patent document. 9 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 9 Applicant is to place a check mark here if English language Translation is alloched.

PTO/SB/08A (08-00)

e type a plus sign (+) inside this box + + Approved for use through 10/31/2002. OMB 0831-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number

PE JO SW	bslitute for form 1448A	PTO	····	Camplete If Known			
O NE	ORMATION	DISC	CLOSURE	Application Number	09/518,501		
THE T	ATEMENT BY	/ An	DUCANT	Filing Date	March 3, 2000		
(B)	WIEMENI D	r Ar	PLICANI	First Named Inventor	Erion et al.		
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	_			Group Art Unit	1624		
19 Lott	(use as many	sheels	as necessary)	Examiner Name	T. McKenzie		
PATEIN & Theet	3	of	3	Attorney Docket Number	032465.00013.RCE (CIP1)		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cita No.1	Include name of the sushor (in CAPITAL LETTERS), title of the strictle (when appropriate), title of the item (book, magazine, journal, sental, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T°
81		Starrett, Jr. et al., "Synthesis, Oral Bloavailability Determination, and in Vitro Evaluation of Prodrugs of the Antiviral Agent 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA)," J. Med. Chem., 37:1857-1864 (1994).	
		Thomson et al., "Synthesis, Bioactivation and Anti-HIV Activity of the Bis(4-acyloxybenzyl) and Mono(4-acyloxybenzyl) Esters of the 5'-monophosphate of AZT," J. Chem. Soc., Perk. Trans. 1, (11):1239-1245 (1993).	 -
		Weber and Waxman, "Activation of the Anti-cancer Drug Ifosphamide by Rat Liver Microsomal P450 Enzymes," Biochem. Pharm., 45(8):1685-1694 (1993).	
1		Zon et al., "NMR Spectroscopic Studies of Intermediary Metabolites of Cyclophosphamide. A Comprehensive Kinetic Analysis of the Interconversion of cis- and trans-4- Hydroxycyclophosphamide with Aldophosphamide and Concomitant Partitioning of Aldophosphamide Between Irreversible Fragmentation and Reversible Conjugation Pathways," J. Med. Chem. 27:466-485 (1984).	

Exampler Date Signature Considered

*EXAMINER: Initial if reference considered, whether or not dilation is in conformance with MPEP 609. Draw the through chatton is not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English tanguage Translation is attached.

			1011E				Deep 4 of 0
		FORM PTO-1449	um 2 8 2005 6	ATTY. DOCKET NO -2358.0010002/RWE	CJW	APPLICATION NO. 09/518,501	Page 1 of 3
				FIRST NAMED INVEN	TOR		
INFO	RMATION	DISCLOSURE	MATEMENT	FILING DATE		ART UNIT	
			TRADEMA	March 3, 2000	-	1624	
			U.S. PA	TENT DOCUMENTS	<u> </u>		
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-ÇLASS	FILING DATE
1	AA1	3,404,178	10/01/1968	Roy, C.H.	05.00	1000 100	10/07/1965
9							
	AB1	4,621,077	11/04/1986	Rosini et al.			06/08/1984
	AC1	4,659,825	04/21/1987	Holy et al.			01/06/1984
	AD1	4,705,651	11/10/1987	Staibano			10/11/1985
	AE1	4,724,232	02/09/1988	Rideout et al.			09/17/1985
	AF1	4,724,233	02/09/1988	De Clercq et al.			04/21/1986
	AG1	4,777,163	10/11/1988	Bosies et al.			07/24/1987
	AH1	4,808,716	02/28/1989	Holy et al.			04/25/1986
	Al1	4,861,759	08/29/1989	Mitsuya et al.			08/11/1987
1	AJ1	4,879,277	11/07/1989	Mitsuya et al.			08/11/1987
	AK1	4,882,142	11/21/1989	Simon et al.			12/19/1988
			FOREIGN F	PATENT DOCUMEN	ITS	, , , , , , , , , , , , , , , , , , , ,	
EXAMINER		DOCUMENT					
INITIAL		NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
							Yes
	AM						No Yes
	AN						No
		-					Yes
	AO						No Yes
	AP	OTHER	Including Author	 or, Title, Date, Perti	nent Pages e	tc)	No.
		OTTL	V (including Autho	or, ritie, Date, Perti	ient rages, e	10.)	
.•	AR						
	AS						
	AT			·			
EXAMINER	M-	11/10 16	ees.		DA	TE GONSIDE BED	
EXAMINER:	ital if relete	ende considered, w	hether or hot citation is	in conformance with MPE	P 609. Draw line	through citation if no	t in conformance
and not denside	ered. Includ	te copy of this form	with next communication	on to Applicant.			

OIFE			
(0)		Page 2 of 3	•
JUN 2 8 2005 G	ATTY, DOCKET NO. 2358.0010002/RWE/CJW	APPLICATION NO. 09/518,501	
KA G	FIRST NAMED INVENTOR Erion et al.		
INFORMATION DISCLOSURE STATEMENT	FILING DATE	ART UNIT	
•	March 3, 2000	1624	

					<u>U.S.</u>	PATENT DOCUMENT	S				
EXAMIN	ER		DOC	UMENT			0.40	_	0110 01	1	
INITIAL		100	NUM	BER	DATE	NAME	CLAS	S	SUB-CL/	<u> 188</u>	FILING DATE:
) =	1	AA2	4,898		02/06/1990	Simon et al.					05/14/1987
		AB2	4,939	9,130	07/03/1990	Jaeggi et al.					02/27/1989
		AC2	5,034	1,394	07/23/1991	Daluge					12/22/1989
		AD2	5,047	7,533	09/10/1991	Reist et al.					01/22/1990
		AE2	5,089	,500	02/18/1992	Daluge					05/08/1991
		AF2	5,153	3,183	10/06/1992	Kawabe et al.					05/06/1991
		AG2	5,210),085	05/11/1993	Liotta et al.					02/22/1991
		AH2	5,240),946	08/31/1993	Kinney et al.					04/29/1992
		Al2	5,246	6,937	09/21/1993	Harnden et al.					01/22/1992
	1	AJ2	5,366	6,965	11/22/1994	Strein					01/29/1993
Q		AK2	5,480),875	01/02/1996	Isomura et al.					371 Date: 12/21/1994
1		· · · · · · · · · · · · · · · · · · ·	*	······································	FOREIG	N PATENT DOCUME	NTS				
EXAMIN INITIAL	ER			CUMENT MBER	DATE	COUNTRY	CLA	ss	SUB-CL/	ASS	TRANSLATION
		AL									Yes No
-		AM									Yes No
	,	AN									Yes No
		AO									Yes No
		AP					_				Yes No
				OTHER (Including Au	ithor, Title, Date, Perl	inent Pages,	etc.			
	,	AR									, . , .
		AS					·				
		АТ								/	
EXAMIN	ER	De	, /	11/10 1	ep.			ATE	CONSTRE	KED	67
EXAMINE and not	R: Init	ial if refer	ence conv	of this form w	ether of not citatio	on is in conformance with Mi	PEP 609. Draw li	ne thr	ough citatio	n if no	t in conformance

	Page 3 of 3
ATTY. DOCKET NO. 2358.0010002/RWE/CJW	APPLICATION NO. 09/518,501
FIRST NAMED INVENTOR	
FILING DATE	ART UNIT
March 3, 2000	1624
	2358.0010002/RWE/CJW FIRST NAMED INVENTOR Erion et al. FILING DATE

			_		U.S.	PATENT DOCUMEN	TS		
EXAMIN	IER			MENT					
INITIAL			NUMB		DATE	NAME	CLASS	SUB-CLASS	
/	\cup	AA3	5,532,	225	07/02/1996	Reist et al.			07/31/1992
		AB3	5,583,	122	12/10/1996	Benedict et al.			12/06/1985
		AC3	5,663,	159	09/02/1997	Starrett, Jr. et al.			10/11/1994
		AD3	5,681,	590	10/28/1997	Bechard et al.			371 Date: 07/26/1995
		AE3	5,721,	219	02/24/1998	Ingall et al.			08/09/1995
		AF3	5,814,	639	09/29/1998	Liotta et al.			02/16/1993
		AG3	5,840,	716	11/24/1998	Ubasawa et al.		1-1-	01/17/1997
·		АН3	5,869,	467	02/09/1999	Holy et al.			03/28/1995
()		Al3	5,914,	331	06/22/1999	Liotta et al.	1		06/07/1995
		AJ						 	
		AK							
		-	1	 ,-	FOREIG	N PATENT DOCUM	ENTS		
EXAMIN	ER			UMENT					
INITIAL			NUM	BER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION"
	<	AL				1)			Yes No
		AM							Yes No
		Aivi	_						Yes
		AN							No Yes
		AO							No
•		AP							Yes No
				OTHER (Including Au	ithor, Title, Date, Pe	rtinent Pages, etc.)		
		AR							
		AS							
		AT .			10			, ,	
EXAMIN	ER	1	, ,	1/0/	<u></u>		DATE	PONSIDERED	
EXAMINE and not co	R: Initi onsidere	al if refered. Include	erice gor de copy	nsidered, whe	other or not citation ith next commun	on is in conformance with Nication to Applicant.	MPEP 609. Draw line thr	ough citation if no	t in conformance

403868_3.DOC

SKGF Rev. 12/03/03